
Retina
Latest News
CME Content


No effect when used with orthokeratology lenses for 2 years.

Treatment and reduces burden of care, providing a treatment option for patients diagnosed with diabetic macular edema.

According to the company, the study assesses the safety and tolerability of a single dose of CLS-AX administered to patients diagnosed with wet AMD by suprachoroidal injection.

According to the company, new imaging options presenting opportunity for better outcomes for patients.

According to the Nanoscope Therapeutics, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

A novel computational platform developed by researchers from the University of Pittsburgh School of Medicine identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

According to the company, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

The effects of cataract surgery are generally evaluated based on improvements in vision, but investigators sought to identify if the structures in the back of the eye were affected as well.

The findings could lead to a new understanding of unexplained causes of heritable retinal diseases.

Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.

LBS-008 is the company’s orally administered tablet for the treatment of Stargardt disease. There are currently no FDA approved treatments for Stargardt disease or dry AMD.

NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.


Physicians use a new administration method to treat patients diagnosed with noninfectious uveitis.

A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research in Poland, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.

At ASRS 2022, Dr Sally Ong presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicentre Study.” Here she shares the biggest takeaways.

Nadia K. Waheed, MD, MPH, and David M. Brown, MD, provide expert advice on techniques to numb the eye before intravitreal injections.

Nadia K. Waheed, MD, MPH; and David M. Brown, MD, discuss barriers to step therapy and the impact of the COVID-19 pandemic on intravitreal injections.

At ASRS 2022, Sunir Garg, MD, FACS, discussed his talk entitled, “Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry.”

Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.

The ASRS See for a Lifetime See a Retina Specialist initiative will spotlight early detection and outline the importance of seeing a retina specialist.

According to the company, pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration.

At ASRS 2022, Sally Ong, MD, presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study.” Here she shares the biggest takeaways.

The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.























